 "Strides Pharma Science's arm gets USFDA nod to market laxative drug in US")
Drug firm Strides Pharma Science's subsidiary has received approval from the US health regulator to market laxative Polyethylene Glycol 3350 and Electrolytes for Oral Solution.
Strides Pharma Global, Singapore, has received approval for Polyethylene Glycol 3350 and Electrolytes for Oral Solution USP in the strengths of 236 grams/2.97 grams/6.74 grams/5.86 grams/22.74 grams/4 Liter from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a filing to BSE.
The approved product is a generic version of GoLYTELY of Braintree Laboratories.
With the current approval, Strides now offers a complete range of PEG 3350 Laxatives for the US markets comprising of three approved products addressing a combined prescription and OTC opportunity of $400 million as per IMS and IRi data, the company said.
The product will be manufactured at Strides' facility in Bengaluru and will be marketed by Strides Pharma in the US market.
Shares of Strides Pharma Science were trading 1.09 per cent lower at Rs 455 apiece on BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app